Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Infectious Disorders - Drug Targets (Formerly Current Drug Targets - Infectious Disorders)
  4. Fast Track Articles
  5. Fast Track Article
image of Significant Microbial Pathogenesis Perspective of Biliary Diseases

Abstract

This review explores various biliary tract diseases caused by different organisms, including cholelithiasis, hepatolithiasis, and choledocholithiasis. The biliary tract's primary functions include collecting, storing, concentrating, and delivering bile juice produced by the liver. Neurohormonal systems involving the vagus and splanchnic nerves, alongside cholecystokinin, regulate gallbladder movement during fasting and digestion. Under normal conditions, bile acids play a crucial role, with approximately 95% being reabsorbed by the intestinal epithelium and returned to the liver the portal vein system. The liver, often hailed as a miracle worker, detoxifies, purifies, and regenerates, performing essential functions in the body. Recent research indicates that the gallbladder, akin to the intestine, harbors a diverse microbiota. Additionally, the biliary mucosa features chemical, mechanical, and immunological barriers that promote immunological tolerance. Hepatotoxicity remains a significant global health concern and a leading cause of mortality. Providing clear and accurate information on liver toxicity is critical, especially in the context of medication safety and public health. By refining these elements, this review can effectively convey the complexity and importance of biliary tract diseases and liver function in health and disease contexts.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/iddt/10.2174/0118715265302000240913092037
2024-10-29
2025-01-19

  • From This Site

    /content/journals/iddt/10.2174/0118715265302000240913092037
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Behar J. Physiology and pathophysiology of the biliary tract: the gallbladder and sphincter of Oddi-a review. ISRN Physiol. 2013 2013 837630 10.1155/2013/837630
    [Google Scholar]
  2. Pradhan S.B. Dali S. Relation between gallbladder neoplasm and Helicobacter hepaticus infection. Kathmandu Univ. Med. J. 2004 2 4 331 335 16388245
    [Google Scholar]
  3. GBD Mortality and causes of death, collaborators. Global regional and national age sex specific all cause and cause specific mortality for 240 causes of death, 1990-2013: a systemic analysis for the global burden of disease study. Lancet 2013 385 9963 117 171
    [Google Scholar]
  4. Scott A.J. Bacteria and disease of the biliary tract. Gut 1971 12 6 487 492 10.1136/gut.12.6.487 4933136
    [Google Scholar]
  5. Pandey M. Helicobacter species are associated with possible increase in risk of biliary lithiasis and benign biliary diseases. World J. Surg. Oncol. 2007 5 1 94 10.1186/1477‑7819‑5‑94 17708763
    [Google Scholar]
  6. Neri V. Margiotta M. De Francesco V. Ambrosi A. Valle N.D. Fersini A. Tartaglia N. Minenna M.F. Ricciardelli C. Giorgio F. Panella C. Ierardi E. DNA sequences and proteic antigens of H. pylori in cholecystic bile and tissue of patients with gallstones. Aliment. Pharmacol. Ther. 2005 22 8 715 720 10.1111/j.1365‑2036.2005.02644.x 16197492
    [Google Scholar]
  7. Elkeles G. Mirizzi P.L. A study of the bacteriology of the common bile duct in comparison with the other extrahepatic segments of the biliary tract. Ann. Surg. 1942 116 3 360 366 10.1097/00000658‑194209000‑00007 17858101
    [Google Scholar]
  8. Edlund Y.A. Mollstedt B.O. Ouchterlony O. Bacteriological investigation of the biliary system and liver in biliary tract disease correlated to clinical data and microstructure of the gallbladder and liver. Acta Chir. Scand. 1959 116 5-6 461 476 13660715
    [Google Scholar]
  9. Glenn F. Wantz G.E. Acute cholecystitis following the surgical treatment of unrelated disease. Surg. Gynecol. Obstet. 1956 102 2 145 153 13299028
    [Google Scholar]
  10. McFadyean F. Stockman S. Report of the Department Committee appointed by the Board of Agriculture and Fisheries to inquire into epizootic abortion. London His Majesty’s Stationary Office 1909
    [Google Scholar]
  11. Vinzent R. Dumas J. Picard N. Septicemie grave au cours de la grossesse due a un vibrion: avortiment consecutif. Bull. Acad Natl. Med. 1947 131 90 93
    [Google Scholar]
  12. Fox J.G. Dewhirst F.E. Shen Z. Feng Y. Taylor N.S. Paster B.J. Ericson R.L. Lau C.N. Correa P. Araya J.C. Roa I. Hepatic Helicobacter species identified in bile and gallbladder tissue from chileans with chronic cholecystitis. Gastroenterology 1998 114 4 755 763 10.1016/S0016‑5085(98)70589‑X 9516396
    [Google Scholar]
  13. Mamatha B. Shenoy P.A. Sunil Rodrigues G. Martena Devadas S. Shetty V. Rodney Bangera S. Asha R. Rajini K.V. Shrilaxmi M.S. Biliary tract infections and their Microbiological Spectrum- A study from coastal region of Southern India. Infectio. 2019 23 3 253 258 10.22354/in.v23i3.789
    [Google Scholar]
  14. Chou S.T. Gibson J.B. Experimental cholangitis and cholelithiasis. Br. J. Exp. Pathol. 1968 49 6 565 573 4884386
    [Google Scholar]
  15. Chang K.K. Chang C.L. Tai F.T. Wang C.H. Lin R.C. Empiric antibiotic choices for community-acquired biliary tract infections. Adv Digest Med. 2014 1 54 59 10.1016/j.aidm.2013.09.002
    [Google Scholar]
  16. Al-Zuharri O.A. Isolation and identification of bacteria from patients with cholecystits and cholelithiasis undergoing cholecystectomy. Al-Kufa J Biol. 2011 3 1
    [Google Scholar]
  17. Capoor M.R. Nair D. Rajni Khanna G. Krishna S.V. Chintamani M.S. Aggarwal P. Microflora of bile aspirates in patients with acute cholecystitis with or without cholelithiasis: a tropical experience. Braz. J. Infect. Dis. 2008 12 3 222 225 18839486
    [Google Scholar]
  18. Manan F. Khan M.A. Faraz A. Khan M. Frequency of common bacteria and their antibiotic sensitivity in patients with symptomatic cholelithiasis. J. Postgrad. Med. Inst. 2014 28 2
    [Google Scholar]
  19. van Velkinburgh J.C. Gunn J.S. PhoP-PhoQ-regulated loci are required for enhanced bile resistance in Salmonella spp. Infect. Immun. 1999 67 4 1614 1622 10.1128/IAI.67.4.1614‑1622.1999 10084994
    [Google Scholar]
  20. Chemmanur A.T. Biliary Disease. Medscape 2018
    [Google Scholar]
  21. Ljungh Å. Wadström T. The role of microorganisms in biliary tract disease. Curr. Gastroenterol. Rep. 2002 4 2 167 171 10.1007/s11894‑002‑0055‑6 11900683
    [Google Scholar]
  22. Hofmann A.F. Bile acids: the good, the bad, and the ugly. Physiology (Bethesda) 1999 14 1 24 29 10.1152/physiologyonline.1999.14.1.24 11390813
    [Google Scholar]
  23. Begley M. Sleator R.D. Gahan C.G.M. Hill C. Contribution of three bile-associated loci, bsh, pva, and btlB, to gastrointestinal persistence and bile tolerance of Listeria monocytogenes. Infect. Immun. 2005 73 2 894 904 10.1128/IAI.73.2.894‑904.2005 15664931
    [Google Scholar]
  24. Maseda E. Maggi G. Gomez-Gil R. Ruiz G. Madero R. Garcia-Perea A. Aguilar L. Gilsanz F. Rodriguez-Baño J. Prevalence of and risk factors for biliary carriage of bacteria showing worrisome and unexpected resistance traits. J. Clin. Microbiol. 2013 51 2 518 521 10.1128/JCM.02469‑12 23196362
    [Google Scholar]
  25. Bajaj A. Thakur A. Mishra B. Loomba P.S. Dogra V. Chandak R.J. Rathod P.G. Multidrug resistant bacteria causing biliary tract infection: A tertiary care centre study from North India. Saudi J. Pathol. Microbiol. 2019 4 3 245 249
    [Google Scholar]
  26. Adams D.B. Borowicz M.R. Taylor Wootton F. III Cunningham J.T. Bile duct complications after laparoscopic cholecystectomy. Surg. Endosc. 1993 7 2 79 83 10.1007/BF00704382 8456373
    [Google Scholar]
  27. Gérard P. Metabolism of cholesterol and bile acids by the gut microbiota. Pathogens 2013 3 1 14 24 10.3390/pathogens3010014 25437605
    [Google Scholar]
  28. Brestoff J.R. Artis D. Commensal bacteria at the interface of host metabolism and the immune system. Nat. Immunol. 2013 14 7 676 684 10.1038/ni.2640 23778795
    [Google Scholar]
  29. Verdier J. Luedde T. Sellge G. Biliary mucosal barrier and microbiome. Viszeralmedizin 2015 31 3 156 161 26468308
    [Google Scholar]
  30. Barnes D. Gallbladder and biliary tract disease. Cleavel and Clinic 2010 10.1016/B978‑1‑4160‑6643‑9.00074‑6
    [Google Scholar]
  31. Freeman M.L. Complications of endoscopic biliary sphincterotomy: a review. Endoscopy 1997 29 4 288 297 10.1055/s‑2007‑1004193 9255535
    [Google Scholar]
  32. Csendes A. Fernandez M. Uribe P. Bacteriology of the gallbladder bile in normal subjects. Am. J. Surg. 1975 129 6 629 631 10.1016/0002‑9610(75)90334‑7 805546
    [Google Scholar]
  33. Shenoy S.M. Shenoy S. Gopal S. Tantry B.V. Baliga S. Jain A. Clinicomicrobiological analysis of patients with cholangitis. Int. J. Med. Microbiol. 2014 32 2 157 160 24713902
    [Google Scholar]
  34. Shimada K. Noro T. Inamatsu T. Urayama K. Adachi K. Bacteriology of acute obstructive suppurative cholangitis of the aged. J. Clin. Microbiol. 1981 14 5 522 526 10.1128/jcm.14.5.522‑526.1981 6273452
    [Google Scholar]
  35. Melzer M. Toner R. Lacey S. Bettany E. Rait G. Biliary tract infection and bacteraemia: presentation, structural abnormalities, causative organisms and clinical outcomes. Postgrad. Med. J. 2007 83 986 773 776 10.1136/pgmj.2007.064683 18057178
    [Google Scholar]
  36. Kaya M. Beştaş R. Bacalan F. Bacaksız F. Arslan E.G. Kaplan M.A. Microbial profile and antibiotic sensitivity pattern in bile cultures from endoscopic retrograde cholangiography patients. World J. Gastroenterol. 2012 18 27 3585 3589 10.3748/wjg.v18.i27.3585 22826624
    [Google Scholar]
  37. Rerknimitr R. Fogel E.L. Kalayci C. Esber E. Lehman G.A. Sherman S. Microbiology of bile in patients with cholangitis or cholestasis with and without plastic biliary endoprosthesis. Gastrointest. Endosc. 2002 56 6 885 889 10.1016/S0016‑5107(02)70365‑9 12447303
    [Google Scholar]
  38. Neve R. Biswas S. Dhir V. Mohandas K.M. Kelkar R. Shukla P. Jagannath P. Bile cultures and sensitivity patterns in malignant obstructive jaundice. Indian J. Gastroenterol. 2003 22 1 16 18 12617446
    [Google Scholar]
  39. Katyal A. Bala K. Bansal A. Chaudhary U. Clinico-microbiological analysis of bactibilia isolates in patients of cholecystectomy. Int. J. Res. Med. Sci. 2017 5 9 4030 4035 10.18203/2320‑6012.ijrms20173977
    [Google Scholar]
  40. Barve S. Chen S.Y. Kirpich I. Watson W.H. Mcclain C. Development, prevention, and treatment of alcohol-induced organ injury: the role of nutrition. Alcohol Res. 2017 38 2 289 302 28988580
    [Google Scholar]
  41. Udompap P. Kim D. Kim W.R. Current and future burden of chronic nonmalignant liver disease. Clin. Gastroenterol. Hepatol. 2015 13 12 2031 2041 10.1016/j.cgh.2015.08.015 26291665
    [Google Scholar]
  42. Abdel-Rahman H.G. Abdelrazek H.M.A. Zeidan D.W. Mohamed R.M. Abdelazim A.M. Lycopene: Hepatoprotective and Antioxidant Effects toward Bisphenol A‐Induced Toxicity in Female Wistar Rats. Oxid. Med. Cell. Longev. 2018 2018 1 5167524 10.1155/2018/5167524 30147835
    [Google Scholar]
  43. Zhu R.X. Seto W.K. Lai C.L. Yuen M.F. Epidemiology of hepatocellular carcinoma in the Asia-Pacific region. Gut Liver 2016 10 3 332 339 10.5009/gnl15257 27114433
    [Google Scholar]
  44. Dey P. Saha M. Sen A. Hepatotoxicity and the present herbal hepatoprotective scenario. International Journal of Green Pharmacy 2013 7 4 265 273 10.4103/0973‑8258.122046
    [Google Scholar]
  45. Sharma C.K. Sharma M. Sharma V. Therapeutic potential of a medicinal plant Aegle marmelos (L.) corr.: an insight. J. Environ. Pathol. Toxicol. Oncol. 2016 35 1 1 10 10.1615/JEnvironPatholToxicolOncol.2015014485 27279580
    [Google Scholar]
  46. Sharma M. Yadav I. Sharma C.K. Histopathological evaluation of hepatoprotective activity of Aegle marmelos (l.) corr. against carbon tetrachloride induced toxicity. Ecol Environ and Conser. 2019 25 3 1343 1346
    [Google Scholar]
  47. Singh R.K. Sharma M. Sharma C.K. Protective mechanism of Vitis vinifera L. Fruit (V. Vinifera) loaded polymeric nanoparticles on acute liver injury induced by acetaminophen toxicity. Int. J. Biol. Pharm. Allied Sci. 2022 11 11 5195 5210
    [Google Scholar]
  48. Pathak P. Sharma C.K. Biogenic metallic nanoparticles and their anticancer activities: Biotechnological perspectives. Res. J. Biotechnol. 2021 16 11 177 185 10.25303/1611rjbt177185
    [Google Scholar]
  49. Sharma M. Yadav I. Sharma C.K. Therapeutic efficacy of hepatoprotective activity of Aegle marmelos (L.) Corr. fruit against carbon tetrachloride induced damage in rats. Int. j. Agricult. Stat. Sci. 2019 15 1 175 181
    [Google Scholar]
  50. Sharma M. Yadav I. Sharma C.K. Applications of novel polymeric nanoparticles and natural plant products in drug delivery for various therapeutic purposes. Int. j. Agricult. Stat. Sci. 2018 14 2 529 537
    [Google Scholar]
  51. Sharma C.K. Sharma M. Sharma V. Therapeutic potential of medicinal plants in the drug development against cancer and hepatic injury- An overview. Vegetos. 2018 31 87 92
    [Google Scholar]
  52. Bruchez P. Pittet A. Magistretti P.J. Toxicity of chemicals: a case study of carbon tetrachloride. Toxicol. Lett. 1998 100 1-3 387 395
    [Google Scholar]
  53. Jaeschke H. McGill M.R. Ramachandran A. Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: Lessons learned from acetaminophen hepatotoxicity. Drug Metab. Rev. 2012 44 1 88 106 10.3109/03602532.2011.602688 22229890
    [Google Scholar]
  54. Fattovich G. Stroffolini T. Zagni I. Donato F. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 2004 127 5 Suppl. 1 S35 S50 10.1053/j.gastro.2004.09.014 15508101
    [Google Scholar]
  55. Coe M. Shiran M. Spector E. Xenobiotics and liver injury. Toxicol. Sci. 2002 65 2 166 176 11812920
    [Google Scholar]
  56. Lu Y. Cederbaum A.I. Autophagy C. Research: oxidative stress and antioxidant defense mechanisms in the liver. Oxid. Med. Cell. Longev. 2019 2019 1 15
    [Google Scholar]
  57. Friedman S.L. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008 134 6 1655 1669 10.1053/j.gastro.2008.03.003 18471545
    [Google Scholar]
  58. Kunjiappan S. Bhattacharjee C. Chowdhury R. Hepatoprotective and antioxidant effects ofAzolla microphylla based gold nanoparticles against acetaminophen induced toxicity in a fresh water common carp fish (Cyprinus caprio). Nanomed. J. 2015 2 2 88 110
    [Google Scholar]
  59. Ye C. Dong C. Lin Y. Shi H. Zhou W. Interplay between the Human Microbiome and Biliary Tract Cancer: Implications for Pathogenesis and Therapy. Microorganisms 2023 11 10 2598 10.3390/microorganisms11102598 37894256
    [Google Scholar]
  60. Wang K. Wang S. Qin X. Chen Y. Chen Y. Wang J. Zhang Y. Guo Q. Zhou C. Zou D. The causal relationship between gut microbiota and biliary tract cancer: comprehensive bidirectional Mendelian randomization analysis. Front. Cell. Infect. Microbiol. 2024 14 1308742 10.3389/fcimb.2024.1308742 38558852
    [Google Scholar]
  61. Wheatley R.C. Kilgour E. Jacobs T. Lamarca A. Hubner R.A. Valle J.W. McNamara M.G. Potential influence of the microbiome environment in patients with biliary tract cancer and implications for therapy. Br. J. Cancer 2022 126 5 693 705 10.1038/s41416‑021‑01583‑8 34663949
    [Google Scholar]
  62. Bridgewater J. Galle P.R. Khan S.A. Llovet J.M. Park J.W. Patel T. Pawlik T.M. Gores G.J. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J. Hepatol. 2014 60 6 1268 1289 10.1016/j.jhep.2014.01.021 24681130
    [Google Scholar]
  63. Brindley P.J. Bachini M. Cholangiocarcinoma. Nat. Rev. Dis. Primers 2021 7 65
    [Google Scholar]
  64. Ciombor K.K. Goff L.W. Advances in the management of biliary tract cancers. Clin. Adv. Hematol. Oncol. 2013 11 1 28 34 23416860
    [Google Scholar]
  65. Nakamura H. Arai Y. Totoki Y. Shirota T. Elzawahry A. Kato M. Hama N. Hosoda F. Urushidate T. Ohashi S. Hiraoka N. Ojima H. Shimada K. Okusaka T. Kosuge T. Miyagawa S. Shibata T. Genomic spectra of biliary tract cancer. Nat. Genet. 2015 47 9 1003 1010 10.1038/ng.3375 26258846
    [Google Scholar]
  66. Li Y. Song Y. Liu S. The new insight of treatment in Cholangiocarcinoma. J. Cancer 2022 13 2 450 464 10.7150/jca.68264 35069894
    [Google Scholar]
  67. Koka K. Verma A. Dwarakanath B.S. Papineni R.V.L. Technological Advancements in External Beam Radiation Therapy (EBRT): An Indispensable Tool for Cancer Treatment. Cancer Manag. Res. 2022 14 1421 1429 10.2147/CMAR.S351744 35431581
    [Google Scholar]
  68. Primrose JN Fox RP Palmer DH Malik HZ Prasad R Mirza D Lancet Oncol. 2014 15 9 943 953 10.1016/S1470‑2045(14)70314‑6 25035291
    [Google Scholar]
  69. Abou-Alfa GK Sahai V Hollebecque A Vaccaro G Melisi D Al-Rajabi R Lancet Oncol. 2021 22 3 427 437 33676604
    [Google Scholar]
  70. Zhu A.X. Finn R.S. Edeline J. Cattan S. Ogasawara S. Palmer D. Verslype C. Zagonel V. Fartoux L. Vogel A. Sarker D. Verset G. Chan S.L. Knox J. Daniele B. Webber A.L. Ebbinghaus S.W. Ma J. Siegel A.B. Cheng A.L. Kudo M. Alistar A. Asselah J. Blanc J-F. Borbath I. Cannon T. Chung K. Cohn A. Cosgrove D.P. Damjanov N. Gupta M. Karino Y. Karwal M. Kaubisch A. Kelley R. Van Laethem J-L. Larson T. Lee J. Li D. Manhas A. Manji G.A. Numata K. Parsons B. Paulson A.S. Pinto C. Ramirez R. Ratnam S. Rizell M. Rosmorduc O. Sada Y. Sasaki Y. Stal P.I. Strasser S. Trojan J. Vaccaro G. Van Vlierberghe H. Weiss A. Weiss K-H. Yamashita T. KEYNOTE-224 investigators Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018 19 7 940 952 10.1016/S1470‑2045(18)30351‑6 29875066
    [Google Scholar]
  71. Doherty M.K. Knox J.J. Al-Rajabi R. Future directions in advanced biliary tract cancer: Immunotherapy and targeted therapies. J. Clin. Oncol. 2021 39 14 1598 1605 33705202
    [Google Scholar]
  72. Javle M. Lowery M. Shroff R.T. Weiss K.H. Springfeld C. Borad M.J. J. Clin. Oncol. 2020 38 28 271 279 31751163
    [Google Scholar]
  73. Valle J. Wasan H. Palmer D.H. Cunningham D. Anthoney A. Maraveyas A. Madhusudan S. Iveson T. Hughes S. Pereira S.P. Roughton M. Bridgewater J. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 2010 362 14 1273 1281 10.1056/NEJMoa0908721 20375404
    [Google Scholar]
  74. Gopal P. Robert M.E. Zhang X. Cholangiocarcinoma: Pathologic and Molecular Classification in the Era of Precision Medicine. Arch. Pathol. Lab. Med. 2024 148 3 359 370 10.5858/arpa.2022‑0537‑RA 37327187
    [Google Scholar]
  75. Chang B.K. Timmerman R.D. Stereotactic body radiation therapy: a comprehensive review. Am. J. Clin. Oncol. 2007 30 6 637 644 10.1097/COC.0b013e3180ca7cb1 18091059
    [Google Scholar]
  76. Taylor A. Powell M.E. Intensity-modulated radiotherapy - what is it? Cancer Imaging 2004 4 2 68 73 10.1102/1470‑7330.2004.0003 18250011
    [Google Scholar]
/content/journals/iddt/10.2174/0118715265302000240913092037
Loading
Significant Microbial Pathogenesis Perspective of Biliary Diseases
Bentham Science Publishers ; https://doi.org/10.2174/0118715265302000240913092037
/content/journals/iddt/10.2174/0118715265302000240913092037
/content/journals/iddt/10.2174/0118715265302000240913092037
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: Biliary diseases, bile, gall bladder, liver, symptoms ; treatments

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test